4//SEC Filing
Liau Gene 4
Accession 0001209191-20-054703
CIK 0001623526other
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 5:43 PM ET
Size
8.8 KB
Accession
0001209191-20-054703
Insider Transaction Report
Form 4
Liau Gene
EVP Research & Preclinical Dev
Transactions
- Sale
Common Stock
2020-10-13$40.00/sh−1,649$65,960→ 13,500 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-10-13−1,649→ 132,417 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (1,649 underlying) - Exercise/Conversion
Common Stock
2020-10-13$0.60/sh+1,649$989→ 15,149 total
Footnotes (2)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001780082
Filing Metadata
- Form type
- 4
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 5:43 PM ET
- Size
- 8.8 KB